Boston Scientific Corporation BSX recently closed the acquisition of Axonics, Inc., a medical technology company focused on the development and commercialization of differentiated devices to treat ...

The trial met its primary safety and efficacy endpoints, demonstrating the device's superiority to oral anticoagulants.

Abbott’s Amulet IDE trial put its left atrial appendage closure device up against the Watchman 2.5, which was approved by the ...

In a report released on November 15, David Rescott from Robert W. Baird maintained a Buy rating on Boston Scientific (BSX – Research Report), ...

AVVIGO is an intravascular ultrasound (IVUS) and fractional flow reserve (FFR) system designed to provide high-quality IVUS ...

Boston Scientific announced the acquisition in January, but the review dragged on after the Federal Trade Commission ...

Boston Scientific Corp. last week announced that it has closed on its acquisition of Irvine-based medical device maker ...

for stroke risk reduction in patients with non-valvular atrial fibrillation following a cardiac ablation were presented at ...

Boston Scientific (NYSE: BSX) today announced the completion of its $3.7 billion acquisition of Axonics, Inc. (Nasdaq: AXNX).

Marlborough, Massachusetts Tuesday, November 19, 2024, 17:00 Hrs [IST] ...